Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Jan

Today In Oncology

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Related Videos

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

ChatGPT May Accurately Answer Common Patient Questions Regarding Gynecologic Cancer

Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women

Most Patients Support Use of AI in Mammogram Readings Survey Reveals

Dual Antigen Targeting of Drug-Resistant Extramedullary Myeloma

Phased Variant ctDNA as Biomarker After First-Line Treatment in LBCL